Back

$Treating Advanced RAI-Refractory DTC: A Two-Way Street: Medical Oncology and Endocrinology$

Treating Advanced RAI-Refractory DTC: A Two-Way Street: Medical Oncology and Endocrinology

Episodes

Specialty:

All

Year:

All

EP. 1: Differentiated Thyroid Cancer: Increasing Incidence

ByLori J. Wirth, MD, Massachusetts General Hospital,Jennifer Sipos, MD, Ohio State University,Frank Worden, MD

December 14th 2020

EP. 2: DTC: Histological Subtypes and Tumor Differentiation

ByLori J. Wirth, MD, Massachusetts General Hospital,Jennifer Sipos, MD, Ohio State University,Frank Worden, MD

December 14th 2020

EP. 3: Role of Radioiodine Treatment in DTC

ByLori J. Wirth, MD, Massachusetts General Hospital,Jennifer Sipos, MD, Ohio State University,Frank Worden, MD

December 21st 2020

EP. 4: Thyrotropin Suppression as DTC Treatment Option

ByLori J. Wirth, MD, Massachusetts General Hospital,Jennifer Sipos, MD, Ohio State University,Frank Worden, MD

December 21st 2020

EP. 5: Clinical Scenarios to Consider for RAI-Refractory DTC

ByLori J. Wirth, MD, Massachusetts General Hospital,Jennifer Sipos, MD, Ohio State University,Frank Worden, MD

January 4th 2021

EP. 6: Discussing Iodine-Refractory DTC With Patients

ByLori J. Wirth, MD, Massachusetts General Hospital,Jennifer Sipos, MD, Ohio State University,Frank Worden, MD

January 4th 2021

EP. 7: Management of DTC in Clinical Practice

ByLori J. Wirth, MD, Massachusetts General Hospital,Jennifer Sipos, MD, Ohio State University,Frank Worden, MD

January 11th 2021

EP. 8: Roles and Communication in Treatment in DTC

ByLori J. Wirth, MD, Massachusetts General Hospital,Jennifer Sipos, MD, Ohio State University,Frank Worden, MD

January 11th 2021

EP. 9: Understanding Sequencing and What to Look for in DTC

ByLori J. Wirth, MD, Massachusetts General Hospital,Jennifer Sipos, MD, Ohio State University,Frank Worden, MD

January 18th 2021

EP. 10: Approaching Treatment of Low-Volume DTC

ByLori J. Wirth, MD, Massachusetts General Hospital,Jennifer Sipos, MD, Ohio State University,Frank Worden, MD

January 18th 2021

EP. 11: Multidisciplinary Management for the Treatment of DTC

ByLori J. Wirth, MD, Massachusetts General Hospital,Jennifer Sipos, MD, Ohio State University,Frank Worden, MD

January 18th 2021

EP. 12: RAI-Refractory DTC Trials: Phase 3 DECISION and SELECT

ByLori J. Wirth, MD, Massachusetts General Hospital,Jennifer Sipos, MD, Ohio State University,Frank Worden, MD

January 21st 2021

EP. 13: Sorafenib and Lenvatinib Side Effect Profile and Dosing

ByLori J. Wirth, MD, Massachusetts General Hospital,Jennifer Sipos, MD, Ohio State University,Frank Worden, MD

January 21st 2021

EP. 14: Molecular Testing in Treatment Selection

ByLori J. Wirth, MD, Massachusetts General Hospital,Jennifer Sipos, MD, Ohio State University,Frank Worden, MD

January 28th 2021

EP. 15: Advice for Managing RAI-Refractory DTC

ByLori J. Wirth, MD, Massachusetts General Hospital,Jennifer Sipos, MD, Ohio State University,Frank Worden, MD

January 28th 2021

EP. 16: LIBRETTO-001 Phase 1/2 Trial Overview

ByLori J. Wirth, MD, Massachusetts General Hospital,Jennifer Sipos, MD, Ohio State University,Frank Worden, MD

February 4th 2021

EP. 17: Rationale for Sequencing in Second Line

ByLori J. Wirth, MD, Massachusetts General Hospital,Jennifer Sipos, MD, Ohio State University,Frank Worden, MD

February 4th 2021

EP. 18: The Future of RAI-Refractory DTC Management

ByLori J. Wirth, MD, Massachusetts General Hospital,Jennifer Sipos, MD, Ohio State University,Frank Worden, MD

February 11th 2021

EP. 19: Treating BRAF V600 and NTRK Gene Fusion Positivity

ByLori J. Wirth, MD, Massachusetts General Hospital,Jennifer Sipos, MD, Ohio State University,Frank Worden, MD

February 11th 2021

Treating Advanced RAI-Refractory DTC: A Two-Way Street: Medical Oncology and Endocrinology

Episodes

EP. 1: Differentiated Thyroid Cancer: Increasing Incidence

EP. 2: DTC: Histological Subtypes and Tumor Differentiation

EP. 3: Role of Radioiodine Treatment in DTC

EP. 4: Thyrotropin Suppression as DTC Treatment Option

EP. 5: Clinical Scenarios to Consider for RAI-Refractory DTC

EP. 6: Discussing Iodine-Refractory DTC With Patients

EP. 7: Management of DTC in Clinical Practice

EP. 8: Roles and Communication in Treatment in DTC

EP. 9: Understanding Sequencing and What to Look for in DTC

EP. 10: Approaching Treatment of Low-Volume DTC

EP. 11: Multidisciplinary Management for the Treatment of DTC

EP. 12: RAI-Refractory DTC Trials: Phase 3 DECISION and SELECT

EP. 13: Sorafenib and Lenvatinib Side Effect Profile and Dosing

EP. 14: Molecular Testing in Treatment Selection

EP. 15: Advice for Managing RAI-Refractory DTC

EP. 16: LIBRETTO-001 Phase 1/2 Trial Overview

EP. 17: Rationale for Sequencing in Second Line

EP. 18: The Future of RAI-Refractory DTC Management

EP. 19: Treating BRAF V600 and NTRK Gene Fusion Positivity

Trending on OncLive

FDA Approves Tucatinib Plus Trastuzumab/Pertuzumab as First-Line Maintenance in Advanced HER2+ Breast Cancer

VIR-5500 Receives FDA Fast Track Designation in mCRPC

The OncFive: Top Oncology Articles for the Week of 10/4/2026

FDA Approves Atezolizumab Plus Chemo for Stage III dMMR Colon Cancer

Iberdomide Plus Daratumumab/Dexamethasone Yields Significant PFS Benefit in R/R Myeloma